Faropenem Susceptibility of Multidrug-resistant Contemporary Clinical Isolates from Zhejiang Province, China

Abstract

Alternative antimicrobial therapies are urgently needed for a variety of multidrug-resistant bacterial pathogens. Faropenem is an orally available b-lactam in the class of carbapenem antibiotics. Thus far, little information is available on faropenem susceptibility of multidrug-resistant clinical isolates from China. Therefore, in the current study 141 contemporary clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA: n = 18), coagulase-negative staphylococci (CNS: n = 16), Enterococcus faecalis (n = 14), Enterococcus faecium (n = 7), Pseudomonas aeruginosa (n = 25), Klebsiella pneumoniae (n = 21), Escherichia coli (n = 20), and Acinetobacter baumannii (n = 20), were collected between March 2018 and March 2019 and tested for susceptibility to faropenem and other antimicrobials using the broth microdilution method. All E. faecium, P. aeruginosa, and A. baumannii isolates were fully resistant to faropenem. However, most of the MRSA, CNS, E. faecalis, K. pneumonia, and E. coli isolates appeared to be susceptible to faropenem, with minimal inhibitory concentration90 values of 4 mg/L, 2 mg/L, 2 mg/L, 4 mg/L, and 2 mg/L, respectively. Therefore, faropenem could be considered as alternative therapy for future treatment of multidrug-resistant MRSA, CNS, E. faecalis, K. pneumonia, and E. coli infections in China.